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Abstract: The number of Americans who are suffering from late diagnoses of Alzheimer’s disease 
(AD) increases in the U.S. each year. Therefore, there is a need for more access toward early 
detection of this disease in order to ensure optimal quality of life and treatments for individuals. AD 
is one of the leading causes of deaths and, with the lack of funds for research, the number of AD 
diagnoses is expected to continue to increase. Medicare, Medicaid, and National Institute of Health 
services are providing funds for the current issues, however, it is not enough. There are many forms 
of poor access to services for individuals to seek early detection, but if that can change and financial 
assistance is provided, not only would many more individuals and their families benefit, but the 
states and nation would as well.  
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Alzheimer’s disease is a terminal illness that affects an 
individual’s cognition. Although the disease is a condition that 
is typically recognized in late adulthood, signs of memory loss 
can occur as early as in the third decade of life (Ahmed, Baker, 
& Butler, 2016). Currently, AD is the sixth leading cause of 
death in the United States and every 65 seconds someone 
develops the disease (Medletter Associates, 2015). With such a 
high prevalence of AD, our nation is greatly impacted, and 
changes need to be made. Care for AD is extremely expensive, 
and without an increase in funding for research, there may never 
be a cure.  
National and State Healthcare Issue 
Of all diseases affecting Americans, AD is the most 
expensive, totaling to roughly 277 billion dollars in 2018 
(Alzheimer’s Association, 2019). Among those billions of 
dollars, about 186 billion came from Medicare and Medicaid 
(“Alzheimer's Disease Facts and Figures,” 2018). These state 
and nationally funded programs are spending the most amount 
of the American tax dollars on this disease, yet, even with 
society’s contribution to the taxes, there is hardly any progress 
in AD research for a prevention or cure, as the money is 
predominately used for maintenance of care for those already 
diagnosed (Alzheimer’s Association, 2019). If AD diagnoses 
could be made earlier, less of the Medicare and Medicaid 
dollars would be spent on treating this diagnosis. Indeed, if this 
were the case, the individuals would be receiving assistance 
sooner and, as a result, would be able to plan out their desired 
course of treatment throughout a longer span than an individual 
who is diagnosed later and needs serious and constant medical 
attention (Alzheimer’s Association, 2019). Perhaps most 
importantly, this change could allocate a larger portion of the 
Medicare and Medicaid’s assistance toward finding a 
prevention or cure. “Among all Americans alive today, if those 
who will get Alzheimer's disease were diagnosed when they had 
mild cognitive impairment, before dementia, it would 
collectively save $7 trillion to $7.9 trillion in health and long-
term care costs” (Alzheimer's Disease Facts and Figures, 2018, 
p. 57).   
In addition to this being a huge shift in research, this would 
also mean that another large portion of the money could be 
spent on imaging and neurological examinations which are 
greatly needed to diagnose individuals. Indeed, although these 
tests are costly, they are essential to officially determine if the 
individual truly has AD. In addition, if the individual has the 
access for these images and exams early, it will save them 
money overall. From a national healthcare perspective, there is 
also less of an expense for AD discovered while the individual 
is in the mild cognitive impairment stage, compared to 
diagnosing the disease while the individual has progressed to 
the dementia stage (Alzheimer’s Association, 2019). This is due 
to the rapid spikes in costs directly before and after late 
diagnosis (Alzheimer’s Association, 2019). Indeed, because 
individuals diagnosed with AD in the mild cognitive 
impairment stage have had time to plan their medical future and 
are aware of the cause of their illness, by the time they have 
reached the dementia stage, they have significantly less long-
term care and medical costs. Furthermore, by the time of 
reaching dementia, these individuals have their mild cognitive 
impairments controlled and managed (Alzheimer’s 
Association, 2019). Unfortunately, those diagnosed late also 
have unmanaged mild cognitive impairment, which likely 
resulted in many doctors’ visits and unnecessary costs toward 
symptom control, and could have been managed by a 
neurological examination to pinpoint the illness and begin 
treatment (Alzheimer’s Association, 2019). Then, all at once, 
the individual diagnosed late may need the medical imaging and 
many other tests in a short period of time, in addition to other 
long-term and constant care, which are large expenses 
(Alzheimer’s Association, 2019). 
Impacts on Delivery of Healthcare 
Access to early detection of AD allows individuals to have 
options for various forms of testing. Most recently, research has 
shown that the use of biomarkers in relation to cerebral spinal 
fluid has been found to show the earliest indications of the 
development of mild cognitive impairment (Buracchio & Kaye, 
2009). Unfortunately, these tests and procedures are extremely 
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costly. Indeed, this can become a financial burden to the 
individual and the family, if even affordable. Currently, 
Medicare covers tests such as blood studies, urinalysis, 
electrocardiograms, chest X-rays, computerized tomography 
(CT) scans, electroencephalography (EEG), and magnetic 
resonance imaging (MRI) to assist in the diagnostic process. 
Positron emission tomography (PET) scans have been shown to 
be one of the better tools to assist in diagnosis, as they examine 
the deposits of amyloid protein plaque in the brain, which can 
occur years before any clinical signs of AD (Marcus, Mena, & 
Subramaniam, 2014). Furthermore, these scans can even show 
differentiation to target the specific type of dementia, including 
AD (Marcus, Mena, & Subramaniam, 2014). However, when 
used for diagnosing AD, they are very rarely covered by 
Medicare (Alzheimer’s Association, 2019). Without the 
financial assistance of Medicare, individuals likely suffer a lack 
of access to this very important test. Indeed, PET scans play an 
integral role in the diagnostic process, and should be covered 
by Medicare, especially for individuals with AD. With the 
prevalence of the disease increasing, it is vital to locate and 
share information about early detection. If caught early, many 
cases could begin receiving treatments and develop a plan of 
action before the disease takes the majority of the person’s 
cognition (Marcus, Mena, & Subramaniam, 2014).  
Population Impacted 
Many individuals, families, and workers are affected by 
Alzheimer’s disease. Indeed, as of 2018, 5.5 million Americans 
over the age of 65 have a diagnosis of AD, and, with the baby 
boomer generation aging, this statistic is expected to 
dramatically increase for the next several decades 
(“Alzheimer's Disease Facts and Figures,” 2018). This illness is 
not a small matter. It affects millions of individuals in this 
country and will continue to develop and impact more if 
significant changes are not made.  
When considering AD and the population that it affects, it 
is common to focus on the individual, however, the family and 
caregivers also play roles into the individual’s access for care. 
Family, close friends, and other unpaid workers make up 83 
percent of aid for the late adulthood population. Nearly half of 
all care giving are for individuals suffering from AD or 
dementia (Alzheimer’s Association, 2019). These caregivers 
are working with the AD population in what means may be 
available. This can result in family members assuming that role 
of primary care giver, but they may lack in healthcare 
knowledge which ultimately affects the individual’s care 
(Taylor, Bouldin, & McGuire, 2018). The caregivers may not 
know of the available resources, may know the person cannot 
financially afford testing, or may struggle accepting the harsh 
reality that a person they love has mild cognitive impairments 
and could benefit from early detection (Bynum, 2014). Another 
consideration is the cost to the individual. Even if their care is 
coming primarily from unpaid family members, the financial 
burden on the individual including the costs for comorbidities 
add to an estimated $28,500 per individual per year (Fishman, 
2013). Those costs greatly impact the individual for the access 
of care that they can afford. In addition, if the individual has a 
family, these yearly financial obligations to manage the 
individual’s care could greatly impact the way the whole family 
functions. It could limit the family’s ability to engage in valued 
occupations due to financial means.  
Thesis statement 
More Americans are suffering from late diagnoses of 
Alzheimer’s disease in the U.S. each year. Therefore, there is a 
need for more access toward early detection of this disease in 
order to ensure optimal quality of life and financially affordable 
care.  
 
Relationship 
Connection to Course Content 
When evaluating why individuals may not be tested for AD 
when exhibiting signs of mild cognitive impairment, it is 
important to consider the availability of care. According to Shi 
and Singh (2019), there are dimensions of access that can affect 
an individual’s ability to receive care: availability, accessibility, 
and accommodation. In regards to availability, the family plays 
a critical role. Indeed, if the family does not recognize the need 
for early AD testing, the individual suffers without ever gaining 
the opportunity to be seen by a doctor for early diagnostic 
services. Additionally, another condition may be due to the 
negative stigmas associated with AD. The family of those 
individuals may have a resistant mindset regarding seeking help 
and, therefore, may be hesitant to employ a neurological 
examination. Lastly, another availability consideration is 
financial piece. With current funds, the cost for AD services and 
examinations may be outside of the financial scope. Lastly, AD 
individuals may experience a lack of access to care because they 
simply are not receiving enough assistance to be able to be seen 
by a doctor.  
Another dimension is described as accessibility (Shi & 
Singh, 2019). Accessibility becomes a concern when 
individuals do not have access to a transportation in order to 
travel to a location where there is a knowledgeable AD 
provider. This issue can occur if the individuals do not have 
their own vehicle or do not have the ability to drive themselves 
the distance to the healthcare provider. For example, 
individuals in late adulthood are often limited to driving short 
distances that are 15 minutes or less, however,  it is not 
uncommon to find that the closest medical provider is 45 
minutes away. Individuals in such a predicament are restricted 
to care that could take place in their home or reliance on another 
person to drive them to an appointment. In this dimension of 
care, the transportation limitations are what is keeping the 
individual from quality care (Shi & Singh, 2019).  
In regards to accommodation, scheduling is often the 
primary issue. Indeed, when an individual has concerns 
regarding their mental functioning, the individual’s primary 
care physician sends a referral to a specialist, however, the 
specialized practitioner may not have a work  schedule that 
aligns the individual’s needs (Shi & Singh, 2019). Additionally, 
a second conflict may be the individual’s work schedule. If the 
individual is still working, they may need a very early 
appointment before work, yet the specialist may not come in the 
office until noon. This would delay the individual’s ability to 
be seen by the specialist until there is a match of the two 
schedules, if ever seen at all. Indeed, this may restrict the 
individual from being seen for long periods of time, which 
would delay the individual on a very time sensitive matter (Shi 
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& Singh, 2019). If the individual is not seen due to time 
conflicts, they could be progressing through early stages of AD 
without even knowing it. By the time it is discovered by the 
specialist, the individual may be in a later stage than they would 
have if an appointment could have been made fitting their 
schedule. 
Application to Occupational Science 
Access for early detection of AD can be limited due to 
various types of occupational injustices. Someone that 
experiences occupational deprivation could struggle going to 
the doctor because they may notice a change in their behaviors 
and feel like the memory loss is out of their control (Hasselkus, 
2011). The individual could feel like a piece of their personal 
identity is being taken away by this disease, and seclude 
themself from anything that used to be enjoyable (Kielhofner, 
2008). In addition, this may lead to avoid engaging in 
occupations in which another person might refer them to a 
doctor due to the drastic changes in ability to occupationally 
perform. What level the individual could previously perform at 
may be substantially different than their current abilities, which 
may be noticeable enough to warrant attention.  
On the other hand, individuals may feel their memory 
lapses are temporary, so they refrain from participating in their 
occupations during these particular times of the day and also 
may feel that their memory lapses are not severe enough to see 
a practitioner about the potential condition (Hasselkus, 2011). 
According to Black (2018), symptoms of anxiety may emerge 
when discussing a potential diagnosis of AD to an individual. 
Indeed, this may cause worry and questioning, and lead the 
individual to solitary engagements to avoid any additional 
anxiety. Furthermore, there could be a transition to a denial 
period in which the individual does not believe or truly see the 
reality of their health status (Hasselkus, 2011). This form of 
injustice, called disruption, restricts individual’s access to their 
healthcare needs because they limit their own ability and view 
to see the issue themselves (Hasselkus, 2011).  
Another area to consider is access to medical professionals 
who have a valued sense of client-centered care. In this case, 
the provider is aware and knowledgeable of the client’s 
concerns and behaviors, and provides services that are focused 
on ensuring the best support for that client’s life (Hasselkus, 
2011). By practicing client-centered care, the practitioner can 
promote ideas regarding ways to implement the client’s 
interests within the realms of ability due to AD. For example, 
to encourage a single, male client who enjoys cooking with his 
friends, a provider may recommend that he begin going to 
restaurants with his friends instead. Indeed, this would still 
allow the client to participate in a social activity with his 
friends, but without risking injuring himself in the kitchen while 
cooking. This example is also especially helpful for client-
centered care, not only because it allows the client to engage in 
their interests, but because it is also medically beneficial. 
Engaging in social activities is especially important for 
individuals with AD to promote cognitive functioning and, 
typically, women participate in this more than men (Mielke, 
2018). By providing quality care, the practitioner is able to 
understand clients in a  more holistic manner and truly make a 
bigger difference.  
 
Relevance 
Current Healthcare Policies 
When viewing current healthcare policies, it is important 
to examine the funding and logistics of the available programs 
and services. “In 2011, Congress passed the National 
Alzheimer’s Project which mandated a National Plan to 
Address Alzheimer’s Disease in 2012, that set a target date of 
2025 to develop methods of prevention and effective treatment” 
(Black, 2018). The National Institute of Health (NIH) 
redirected 40 million dollars in the budget to AD research in the 
year 2013 and has continued to be a financial support (Black, 
2018).  Since then, access to healthcare has become more 
affordable and available.  
Drug rebates is an apt example of the increase in access. 
Before funding increases, Medicare had a cap on prescriptions 
and if a patient hit that cap, they would have to pay the rest of 
the amount out of pocket. By 2020, this will be phased out as 
Medicare will cover the full expense (Jiang, Hughes, & Wang, 
2018). Another policy that has been enacted is the use of annual 
wellness visits, which are also funded by Medicare. Although 
these have already been in place, they now include cognitive 
impairment screens to assess for symptoms of AD or dementia, 
as well as talk with the family, caretakers, friends about any 
possible concerns. With this legislature in place, there has been 
an improved delivery on preventative care (Jiang, Hughes, & 
Wang, 2018). 
Unfortunately, the NIH’s contribution to AD is scarce in 
relation to its need. In comparison to funding for other leading 
diseases in the U.S., AD funding is significantly less. Indeed, 
the NIH provides over 6 billion dollars yearly for cancer, which 
is 150 times the amount spent on AD. For yearly funding for 
heart disease, over 4 billion dollars is spent, or 100 times the 
funding given to AD. Lastly, the NIH assistance in HIV/AIDS 
support is over 75 times the amount of AD, adding to the 3 
billion dollars yearly (Black, 2018). Although funding for AD 
is increasing, much more support is needed to make true strides 
in research for such a prevalent disease.  
Implications of Early Detection 
There are many steps that need to be taken for 
improvement of access toward early detection of AD. First and 
foremost, additional funding is crucial for any major progress. 
According to Black (2018), with the limited federal financial 
support, the U.S. is far from finding a cure or even the 
prevention of AD. An avenue that could be taken to increase the 
funding could be advocating for the NIH to reallocate more 
funds for AD research. When evaluating the leading causes of 
death, HIV/AIDS is ranked below AD, yet receives seventy-
five times the funding (Black, 2018). If some funds could be 
reallocated from HIV/AIDS to make a more proportional 
distribution relating to ranking of leading causes of death, there 
could be major improvements and advancements in the AD 
field.  
When considering the individual, going to the doctor and 
having services recommended to be tested for AD in the early 
stages of cognitive decline can result in faster medication 
prescriptions, faster access to a medical specialist concerning 
care, and faster plan of action for the family (Alzheimer’s 
Association. 2019). Early detection gives the individual and 
their family more time to process the hard truth of the terminal 
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illness, but typically provides a longer life span for that 
individual during such a crucial time. While the individual is in 
the early stage of memory loss, they are still mostly themselves 
and can make decisions regarding their future.  
Education for the individuals and their families is another 
area that should be considered. In some cases, when individuals 
who seem to be “too young” for an AD diagnosis, they may be 
dismissed and not taken seriously regarding the various signs or 
symptoms they are experiencing. It can appear as depression or 
stress induced, thus negating to press the individual’s concern 
(Ahmed, Baker, & Butler, 2016). Ultimately, it may even result 
in false reassurance to the individual by examining only the 
status of age (Ahmed, Baker, & Butler, 2016). If there was an 
increase in knowledge about the disease and how early an 
individual can display symptoms, it may help influence the 
individual to take the necessary steps to get tested early, rather 
than wait. In addition, continuing to stay educated and up to 
date about the current AD research could help the practitioner 
to stay alert and aware of young individuals who they might not 
otherwise have expected to have AD (Black, 2019).  
Consequences on Healthcare Service Deliveries 
Early detection for AD may lead to a rise in the 16.1 million 
Americans that are providing unpaid care for these individuals 
(Alzheimer’s Associatio, 2019). Although this may be true, the 
bigger fact to consider is that early detection and diagnosis of 
this disease saves both families and the U.S. government large 
sums of money. Even just a portion of the collective money 
saved could then be turned right back toward the unpaid 
caregivers for this population, reimbursement for neurological 
exams for early testing of AD, and research to find a cure or 
prevention of this terminal illness.   
Early detection of AD provides many benefits. The major 
benefit is through use of exams and testing, which allows the 
practitioner to be certain that the individual does in fact suffer 
from this illness, and that the symptoms are not caused by 
something else. In addition, it provides time for the individuals 
to manage the care of their mild cognitive impairments before 
they progress to a later stage and develop dementia. Another 
benefit is that by detecting the disease early, the family can 
prepare and decide how they will spend their money for the 
journey toward the individual needing constant care and 
medical attention. When viewing the situation through an 
emotional lens, early detection also provides time for the 
individual and family to understand the lifestyle modifications 
and fluctuations, changes in the individual’s perception of their 
quality of life, as well as pushing past the associated stigmas 
and understanding the reality.  
Conclusion 
More Americans are suffering from late diagnoses of 
Alzheimer’s disease in the U.S. each year; therefore, there is a 
need for more access toward early detection of this disease to 
ensure optimal quality of life and treatments for individuals to 
financially afford care. AD can develop in the beginning of 
middle adulthood, but with various reasonings for a lack of 
access to care, they may go untreated for many years. The 
individuals may not be able to afford the cost of testing, may 
avoid testing due to labels and stigma, or may not even 
recognize the extent of their cognitive impairment. More 
governmental assistance needs to be placed into action for 
research and advancements in AD, because without it, AD may 
continue to climb the ladder of leading causes of death and 
affect more and more individuals without ever having a cure.  
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